Exagen price to book ratio XGN

Market value divided by the book value of the company's net assets, since 2019.

Today, Oct 23, 2026: 14.4×
7-year median: 2.9×
Against its 7-year history: 94th; percentile: 0 is its lowest day, 100 its highest
7-year range: 0.6× to 20.4×
Peer median: 2.9×

Exagen's price to book ratio is 14.4× as of Oct 23, 2026.

That is above its 7-year median of 2.9×, higher than on 94% of days in the last 7 years.

Over that time it ranged from 0.6× in Nov 2022 to 20.4× in Jul 2025.

The median for 10 healthcare stocks of a similar size is 2.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	14.4×	3.7×	17.3×
2025	7.7×	4.3×	20.4×
2024	6.5×	1.0×	7.9×
2023	1.2×	0.7×	1.5×
2022	0.7×	0.6×	1.9×
2021	2.1×	1.7×	6.1×
2020	3.8×	2.7×	5.3×
2019	5.5×	3.8×	5.5×

Against its peers

Companies in Healthcare nearest Exagen's size, closest first, today.

Company	Price to book ratio
XGNExagen	14.4×
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
NATRNatures Sunshine Products	1.3×
ELMDElectromed	4.1×
UTMDUtah Medical Products	1.9×
INFUInfuSystem	4.7×
KEQUKewaunee Scientific	1.3×
ICCCImmucell	3.0×
VMDViemed Healthcare	2.6×
EMBCEmbecta	n/m
Peer median	2.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Exagen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.